Genfit (NASDAQ:GNFT) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genfit (NASDAQ:GNFT) in a research note released on Monday morning, Benzinga reports. They currently have a $13.00 price objective on the stock.

Genfit Stock Performance

Shares of Genfit stock opened at $4.19 on Monday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.94 and a current ratio of 2.94. Genfit has a 1 year low of $2.89 and a 1 year high of $6.05. The firm’s 50-day simple moving average is $4.46 and its 200-day simple moving average is $3.94.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. raised its holdings in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the period. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.